464 related articles for article (PubMed ID: 33587652)
1. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
[TBL] [Abstract][Full Text] [Related]
2. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.
Valentino LA; Mamonov V; Hellmann A; Quon DV; Chybicka A; Schroth P; Patrone L; Wong WY;
J Thromb Haemost; 2012 Mar; 10(3):359-67. PubMed ID: 22212248
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
Aledort L; Milligan S; Watt M; Booth J
J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
[TBL] [Abstract][Full Text] [Related]
4. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
[TBL] [Abstract][Full Text] [Related]
6. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.
Blanchette VS; Shapiro AD; Liesner RJ; Hernández Navarro F; Warrier I; Schroth PC; Spotts G; Ewenstein BM;
J Thromb Haemost; 2008 Aug; 6(8):1319-26. PubMed ID: 18503631
[TBL] [Abstract][Full Text] [Related]
7. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
[TBL] [Abstract][Full Text] [Related]
8. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).
Kavakli K; Yang R; Rusen L; Beckmann H; Tseneklidou-Stoeter D; Maas Enriquez M;
J Thromb Haemost; 2015 Mar; 13(3):360-9. PubMed ID: 25546368
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.
Zhao Y; Xiao J; Yang R; Wu R; Hu Y; Beckmann H; Wu J; Hou Q; Sun J
Pediatr Hematol Oncol; 2017 Apr; 34(3):138-148. PubMed ID: 28727494
[TBL] [Abstract][Full Text] [Related]
11. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.
Iorio A; Marcucci M; Cheng J; Oldenburg J; Schoenig-Diesing C; Matovinovic E; Romanov V; Thabane L
Haemophilia; 2014 Nov; 20(6):777-83. PubMed ID: 25039809
[TBL] [Abstract][Full Text] [Related]
12. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.
Konkle BA; Stasyshyn O; Chowdary P; Bevan DH; Mant T; Shima M; Engl W; Dyck-Jones J; Fuerlinger M; Patrone L; Ewenstein B; Abbuehl B
Blood; 2015 Aug; 126(9):1078-85. PubMed ID: 26157075
[TBL] [Abstract][Full Text] [Related]
13. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A.
Auerswald G; Thompson AA; Recht M; Brown D; Liesner R; Guzmán-Becerra N; Dyck-Jones J; Ewenstein B; Abbuehl B
Thromb Haemost; 2012 Jun; 107(6):1072-82. PubMed ID: 22476554
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.
Collins P; Faradji A; Morfini M; Enriquez MM; Schwartz L
J Thromb Haemost; 2010 Jan; 8(1):83-9. PubMed ID: 19817995
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study.
Pollmann H; Klamroth R; Vidovic N; Kriukov AY; Epstein J; Abraham I; Spotts G; Oldenburg J
Ann Hematol; 2013 May; 92(5):689-98. PubMed ID: 23324986
[TBL] [Abstract][Full Text] [Related]
16. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
Mancuso ME; Reding MT; Negrier C; Kerlin BA; Rangarajan S; Simpson ML
Thromb Haemost; 2021 Aug; 121(8):1079-1086. PubMed ID: 33296943
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
[TBL] [Abstract][Full Text] [Related]
19. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
Shah A; Solms A; Garmann D; Katterle Y; Avramova V; Simeonov S; Lissitchkov T
Clin Pharmacokinet; 2017 Sep; 56(9):1045-1055. PubMed ID: 28005225
[TBL] [Abstract][Full Text] [Related]
20. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.
Collins PW; Björkman S; Fischer K; Blanchette V; Oh M; Schroth P; Fritsch S; Casey K; Spotts G; Ewenstein BM
J Thromb Haemost; 2010 Feb; 8(2):269-75. PubMed ID: 19943875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
